
Health Catalyst HCAT
$ 1.87
-4.36%
Quarterly report 2025-Q3
added 11-10-2025
Health Catalyst Cost of Revenue 2011-2026 | HCAT
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Health Catalyst
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 166 M | 164 M | 143 M | 124 M | 98.1 M | 75.3 M | 59.9 M | 43.6 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 166 M | 43.6 M | 109 M |
Quarterly Cost of Revenue Health Catalyst
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 38.5 M | 42.5 M | 43.2 M | - | 42.3 M | 40.1 M | 38.5 M | 41.8 M | - | 36.3 M | - | 34 M | - | 33.1 M | 30.1 M | 27.3 M | - | 24.4 M | 23.1 M | 24.1 M | - | 18.6 M | 17.7 M | 17.3 M | - | 17 M | 12.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 43.2 M | 12.5 M | 30.1 M |
Cost of Revenue of other stocks in the Health information services industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
American Well Corporation
AMWL
|
116 M | $ 5.64 | 3.3 % | $ 90.5 M | ||
|
Accolade
ACCD
|
93.7 M | - | 0.29 % | $ 206 M | ||
|
Cerner Corporation
CERN
|
1 B | - | - | $ 27.9 B | ||
|
Computer Programs and Systems
CPSI
|
176 M | - | 4.4 % | $ 133 M | ||
|
Covetrus
CVET
|
3.72 B | - | - | $ 2.94 B | ||
|
iCAD
ICAD
|
2.97 M | - | - | $ 102 M | ||
|
1Life Healthcare
ONEM
|
319 M | - | - | $ 3.37 B | ||
|
Omnicell
OMCL
|
641 M | $ 41.91 | 0.9 % | $ 1.93 B | ||
|
Akerna Corp.
KERN
|
15.8 M | - | - | $ 161 M | ||
|
HealthStream
HSTM
|
97.9 M | $ 21.98 | -0.34 % | $ 668 M | ||
|
Allscripts Healthcare Solutions
MDRX
|
883 M | - | -10.39 % | $ 886 M | ||
|
Evolent Health
EVH
|
1.04 B | $ 3.3 | -7.18 % | $ 309 M | ||
|
HealthEquity
HQY
|
99.1 M | $ 80.18 | -1.21 % | $ 6.86 B | ||
|
So-Young International
SY
|
568 M | $ 2.93 | 1.74 % | $ 233 M | ||
|
10x Genomics
TXG
|
209 M | $ 22.07 | -1.34 % | $ 2.59 B | ||
|
Veeva Systems
VEEV
|
677 M | $ 192.75 | 2.4 % | $ 30.9 B | ||
|
GoodRx Holdings
GDRX
|
48.2 M | $ 2.29 | 4.82 % | $ 883 M | ||
|
Progyny
PGNY
|
235 M | $ 17.43 | -2.02 % | $ 1.5 B | ||
|
Premier
PINC
|
269 M | - | - | $ 2.33 B | ||
|
Teladoc Health
TDOC
|
772 M | $ 5.07 | -1.27 % | $ 893 M | ||
|
R1 RCM
RCM
|
1.16 B | - | - | $ 3.81 B | ||
|
NantHealth
NH
|
28.8 M | - | -46.64 % | $ 10.4 M | ||
|
OptimizeRx Corporation
OPRX
|
28.6 M | $ 7.53 | -4.32 % | $ 129 M | ||
|
NextGen Healthcare
NXGN
|
275 M | - | - | $ 1.6 B | ||
|
Phreesia
PHR
|
61 M | $ 12.17 | -3.64 % | $ 664 M | ||
|
SCWorx Corp.
WORX
|
2.24 M | $ 0.13 | -6.25 % | $ 190 K | ||
|
Schrödinger
SDGR
|
113 M | $ 12.8 | -2.44 % | $ 940 M | ||
|
Zhongchao
ZCMD
|
6.95 M | $ 1.67 | 0.04 % | $ 8.69 M | ||
|
Signify Health
SGFY
|
440 M | - | -0.02 % | $ 7.21 B | ||
|
Tabula Rasa HealthCare
TRHC
|
233 M | - | - | $ 255 M |